PUXEDDU, ERMANNO
 Distribuzione geografica
Continente #
NA - Nord America 14.256
AS - Asia 1.974
EU - Europa 1.764
SA - Sud America 270
AF - Africa 28
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 8
Totale 18.310
Nazione #
US - Stati Uniti d'America 14.184
SG - Singapore 840
IT - Italia 396
CN - Cina 337
KR - Corea 240
FR - Francia 229
BR - Brasile 220
DE - Germania 212
RU - Federazione Russa 199
HK - Hong Kong 162
IE - Irlanda 161
VN - Vietnam 159
UA - Ucraina 143
PL - Polonia 129
GB - Regno Unito 107
SE - Svezia 51
IN - India 49
JP - Giappone 47
FI - Finlandia 43
CA - Canada 36
BD - Bangladesh 31
NL - Olanda 28
MX - Messico 21
AR - Argentina 19
BE - Belgio 16
ID - Indonesia 12
ES - Italia 11
MY - Malesia 11
TW - Taiwan 11
AU - Australia 9
IQ - Iraq 9
TR - Turchia 9
JM - Giamaica 8
RO - Romania 8
CL - Cile 7
EC - Ecuador 7
KG - Kirghizistan 7
PK - Pakistan 7
SA - Arabia Saudita 7
AT - Austria 6
EG - Egitto 6
AE - Emirati Arabi Uniti 5
CO - Colombia 5
EU - Europa 5
ZA - Sudafrica 5
HU - Ungheria 4
MA - Marocco 4
NG - Nigeria 4
PE - Perù 4
PY - Paraguay 4
TH - Thailandia 4
UZ - Uzbekistan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
CR - Costa Rica 3
GR - Grecia 3
IL - Israele 3
PH - Filippine 3
RS - Serbia 3
VE - Venezuela 3
BH - Bahrain 2
CH - Svizzera 2
GA - Gabon 2
IR - Iran 2
JO - Giordania 2
LB - Libano 2
LT - Lituania 2
LY - Libia 2
PR - Porto Rico 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BW - Botswana 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
GN - Guinea 1
HN - Honduras 1
KE - Kenya 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
NP - Nepal 1
NR - Nauru 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TN - Tunisia 1
Totale 18.310
Città #
Woodbridge 3.479
Wilmington 3.462
Houston 3.407
Fairfield 500
Singapore 467
Ann Arbor 321
Ashburn 293
Chandler 288
San Jose 231
Seattle 221
Cambridge 170
Hong Kong 158
Beijing 144
Dublin 128
Kraków 119
Medford 104
Jacksonville 103
Rome 97
New York 90
Council Bluffs 85
The Dalles 77
Santa Clara 73
Dearborn 69
Los Angeles 59
Lawrence 47
Lauterbourg 45
Tokyo 40
Dallas 39
Ho Chi Minh City 38
Menlo Park 32
Moscow 32
Hanoi 31
Monte Vista 29
San Diego 24
Redwood City 23
Milan 21
Buffalo 20
São Paulo 19
Palo Alto 18
Brussels 16
Naples 16
Helsinki 15
Orem 15
Phoenix 15
Chicago 13
Colorado Springs 13
Redondo Beach 13
Chennai 12
Verona 12
Zhengzhou 12
Denver 11
Guangzhou 11
London 11
Nuremberg 11
Rio de Janeiro 11
Seoul 11
Jakarta 10
Nanjing 10
Stockholm 10
Boardman 9
Frankfurt am Main 9
Munich 9
Norwalk 8
Liverpool 7
New Delhi 7
San Francisco 7
Warsaw 7
Wuhan 7
Amsterdam 6
Atlanta 6
Baghdad 6
Brooklyn 6
Columbus 6
Istanbul 6
Kingston 6
Manchester 6
Mountain View 6
North Bergen 6
Shanghai 6
Belo Horizonte 5
Biberach an der Riss 5
Boston 5
Columbia 5
Genoa 5
Haiphong 5
Hefei 5
Johannesburg 5
Kunming 5
Mexico City 5
Mumbai 5
Mülheim 5
Palermo 5
Pescara 5
Raleigh 5
Santiago 5
Shirwal 5
Surrey 5
Abuja 4
Bologna 4
Cairo 4
Totale 15.089
Nome #
Idiopathic Pulmonary Fibrosis (IPF) incidence and prevalence in Italy 794
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 513
A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD 503
Interaction between corticosteroids and muscarinic antagonists in human airways 503
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network 485
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 485
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. 480
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside 479
Airflow obstruction: Is it asthma or is it COPD? 479
Optimizing drug delivery in COPD: The role of inhaler devices 479
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 477
HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis 463
Acute COPD exacerbation: 3 T MRI evaluation of pulmonary regional perfusion--preliminary experience. 461
M. avium binding to HLA-DR expressed alleles in silico: A model of phenotypic susceptibility to sarcoidosis 459
Metodo per la diagnosi in vitro di fibrosi polmonare/polmonite interstiziale idiopatica e uso di chelanti del ferro per il trattamento della fibrosi polmonare/polmonite interstiziale idiopatica 445
The prevalence of asthma and COPD in Italy: a practice-based study 442
Is allergic sensitization to siberian hamster preventable in high-risk individuals who are already sensitized or exposed to furry animals? 433
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD 432
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 430
Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD 430
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? 428
Iron laden macrophages in idiopathic pulmonary fibrosis: The telltale of occult alveolar hemorrhage? 421
Reactivity to mycobacterial antigens by patients with Lofgren's syndrome as a model of phenotypic susceptibility to disease and disease progression. 419
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study 418
Adherence to COPD treatment: Myth and reality 415
Impact of pulmonary vascular volume on mortality in IPF: Is it time to reconsider the role of vasculature in disease pathogenesis and progression? 409
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis 400
Human embryonic stem cells recover in vivo acute lung inflammation bleomycin-induced 386
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 385
Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine 374
Structured multidisciplinary discussion of HRCT scans for IPF/UIP diagnosis may result in indefinite outcomes 372
Relationship between oxytocin/vasopressin and latex in obstetric surgery: How to recognize (and prevent) allergic reactions and differentiate them from side effects? 371
Dual bronchodilation and exacerbations of COPD 360
Method for in vitro diagnosis of idiopathic pulmonary fibrosis 350
Human embryonic stem cells recover in vivo acute lung inflammation bleomycin-induced 340
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine 253
Olodaterol + tiotropium bromide for the treatment of COPD 243
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 241
Depressive and anxiety symptoms in patients with SARS-CoV2 infection 207
A potential role of triple therapy for asthma patients 188
Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection 185
Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations 177
Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers 162
Does bronchoscopy help the diagnosis in COVID-19 infection? 144
Biomarkers for possible early detection and progression of idiopathic pulmonary fibrosis 136
CD71- Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease 132
Dyspnea perception and neurological symptoms in non-severe COVID-19 patients 118
Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review 86
Experimental glucocorticoid receptor agonists for the treatment of asthma: a systematic review 86
Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients 82
Are there pulmonary sequelae in patients recovering from COVID-19? 79
Indacaterol/Glycopyrronium Combination for COPD 76
Bronchoalveolar lavage (BAL) cells in idiopathic pulmonary fibrosis express a complex pro-inflammatory, pro-repair, angiogenic activation pattern, likely associated with macrophage iron accumulation 70
Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review 63
Lung involvement in psoriatic arthritis patients: cross-sectional study on prevalence, clinical characteristics, and risk factors of a neglected comorbidity 60
Synergy across the drugs approved for the treatment of asthma 59
Expert guidance on the management and challenges of long-COVID syndrome: a systematic review 53
Interaction of phosphodiesterase 3A with brefeldin A-inhibited guanine nucleotide-exchange proteins BIG1 and BIG2 and effect on ARF1 activity 34
Interaction of brefeldin A-inhibited guanine nucleotide-exchange protein (BIG) 1 and kinesin motor protein KIF21A 34
Spontaneous Ventilation Thoracoscopic Lung Biopsy in Undetermined Interstitial Lung Disease: Systematic Review and Meta-Analysis 27
Evaluation of high flow nasal cannulae during endobronchial ultrasound bronchoscopy (EBUS) in high anaesthetic risk patients: a monocentric prospective study 12
null 3
Totale 18.530
Categoria #
all - tutte 43.728
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.728


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202141 0 0 0 0 0 0 0 0 0 0 0 41
2021/2022613 34 56 18 31 25 52 71 28 35 76 52 135
2022/2023691 77 76 22 79 79 144 59 40 58 15 24 18
2023/2024317 46 17 48 9 16 63 18 15 8 16 13 48
2024/20251.365 44 308 135 67 44 92 70 133 143 139 90 100
2025/20262.341 181 131 227 196 206 71 315 251 319 185 168 91
Totale 18.530